Publications
PENELOPE 1-year follow-up: legacy effect of a short protocol-led LDL-C-lowering strategy in patients after myocardial infarction
Marco Alings; Anho Liem; Astrid Schut
Neth Heart J
Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane
Astrid Schut
Cardio-oncology
Routine Spironolactone in Acute Myocardial Infarction
Jan Hein Cornel
N Engl J Med
Colchicine in Acute Myocardial Infarction
Jan Hein Cornel
N Engl J Med
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Gerard Linssen
The New England Journal of Medicine
Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial
Arend Mosterd; Marco Alings; Astrid Schut; Jeroen Schaap; Dirk Lok
European Journal of Heart Failure
Characteristics and Management of Patients With Cancer and Atrial Fibrillation - The BLITZ-AF Cancer Registry
Marco Alings
JACC Advances
Empagliflozin after Acute Myocardial Infarction
The New England Journal of Medicine
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
The New England Journal of Medicine
Effects of a stepwise, structured LDL-C lowering strategy in patients post-acute coronary syndrome
Marco Alings; Anho Liem; Björn Groenemeijer; Astrid Schut
Netherlands Heart Journal
Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)
Marco Alings; Martijn van Eck; Nadea AL Windy
Circulation: Arrhythmia and Electrophysiology
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation J.S. Healey, R.D. Lopes, C.B. Granger, M. Alings, L. Rivard, W.F. McInt
Marco Alings
T h e n e w e ngl a nd j o u r na l o f m e dic i n e
Direct Oral Anticoagulants for Stroke Prevention in Patients with Device- Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials
Marco Alings
Circulation
SELECT
NEJM
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
The New England Journal of Medicine
Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease
Arend Mosterd; Jan Hein Cornel; Stefan Koudstaal; Driek Beelen
European Journal of Preventive Cardiology
Self-administered intranasal etripamil using a symptom- prompted, repeat-dose regimen for atrioventricular-nodal- dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial
Marco Alings; Jaco Houtgraaf
Lancet
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Eelko Ronner
New England Journal of Medicine
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
Fabrice Martens; Aaf Kuijper
Lancet
Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial
Arend Mosterd; Jan Hein Cornel; Eelko Ronner; Paco Prins
Int J Cardiol
The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial
Arend Mosterd; Jan Hein Cornel
Clinical drug investigation
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Jan Willem Borleffs
N Engl J Med
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial
Eur Heart J
Farxiga met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
Marco Alings
Eur Heart J Cardiovasc Pharmacother
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction
Jan Willem Borleffs; Marc van Daele
JACC Heart Failure
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
Fabrice Martens
JACC
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
Acute heart failure and iron deficiency: a prospective, multicentre, observational study
Henri van Dalen; Hans Kragten; Mireille Emans; Clara van Ofwegen-Hanekamp
ESC Heart fail.
Acute heart failure and iron deficiency: a prospective, multicentre, observational study
Henri van Dalen; Hans Kragten; Mireille Emans; Clara van Ofwegen-Hanekamp
ESC Heart fail.
Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome
Aernoud Fiolet; Arend Mosterd; Martijn van Eck; Eugène van Beek; Frank den Hartog; Jan Hein Cornel
Journal of the American College of Cardiology
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
Gerard Linssen
European Heart Journal
Time to commence or time out for colchicine in secondary prevention of cardiovascular disease?
Eur Heart J
Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns
Aernoud Fiolet; Arend Mosterd
Eur Heart J Cardiovasc Pharmacother
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials
Aernoud Fiolet; Arend Mosterd; Jan Hein Cornel
European Heart Journal
OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction
European Journal of Heart Failure
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy
Diabetes Care
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
Hans Kragten
Lancet
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk
JAMA
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
New England Journal of Medicine
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials
European Journal of Heart Failure
Colchicine in Patients with Chronic Coronary Disease
Arend Mosterd; Aernoud Fiolet; Hong Kie The; Timo Lenderink; Pieter Hoogslag; Anastazia Jerzewski; Peter Nierop; Henk Swart; Jeroen Schaap; Aaf Kuijper; Maarten van Hessen; Maurits Dirksen; Marco Alings; Astrid Schut; Jan Hein Cornel
New England Journal of Medicine
Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy
Aernoud Fiolet; Hong Kie The; Arend Mosterd; Jan Hein Cornel
Circulation
Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C- reactive protein
Aernoud Fiolet; Arend Mosterd; Jan Hein Cornel
PLoS One
Cardiac complications in patients hospitalised with COVID-19
Jeroen Schaap
European Heart Journal
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
New England Journal of Medicine
Rationale and design of the AFFIRM‐AHF trial: a randomised, double‐blind, placebo‐controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron‐deficient patients admitted for acute heart failure
Hans Kragten
European Journal of Heart Failure
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Gerard Linssen
Circulation
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial
Gerard Linssen
Circ Heart Fail
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
Marco Alings
Eur J Prev Cardiol
The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.
Aernoud Fiolet; Astrid Schut; Arend Mosterd; Jan Hein Cornel
Am Heart J
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
NEJM
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
Lancet
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Marco Alings
Gastroenterology
Bleeding and New Cancer Diagnosis in Patients with Atherosclerosis
Circulation
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.
Marco Alings
European Heart Journal
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
NEJM
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial
Marco Alings
Gastroenterology
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
Marco Alings
Heart
Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial.
Dirk Lok
ESC Heart fail.
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
New England Journal of Medicine
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
New England Journal of Medicine
Stroke Outcomes in the COMPASS Trial
Marco Alings
Circulation
Prevention of Arrhythmia Device Infection Trial - The PADIT Trial
Marco Alings; Martin Hemels; Leon H R Bouwels; Bob van Vlies
JACC
Prevention of Arrhythmia Device Infection Trial: The PADIT Trial
Marco Alings; Martin Hemels; Leon H R Bouwels; Bob van Vlies
Journal of the American College of Cardiology
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
NEJM
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
NEJM
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
Ton Oude Ophuis
Lancet
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Jan Hein Cornel
The Lancet
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial.
Marco Alings
J Am Coll Cardiol
Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial
Marco Alings; Robert Tieleman; Raymond Tukkie
European Heart Journal
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Gerard Linssen
Circ Heart Fail.
Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial)
Dirk Lok
Am J Cardiol
Inhibition of Interleukin-1b by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease
Jan Hein Cornel
J Am Coll Cardiol
Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.
Marco Alings; Raymond Tukkie; Robert Tieleman
Eur Heart J
Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial
Marco Alings
J Am Heart Assoc
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Marco Alings
Lancet
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.
Marco Alings
Can J Cardiol
Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients: From the WARCEF Trial.
Dirk Lok
JACC Heart Fail
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Jan Hein Cornel
N Engl J Med
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
Marco Alings
N Engl J Med
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial
Marco Alings
Am Heart J
Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS Trial
Jan Hein Cornel
Circulation
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study
Eur Heart J
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure
New England Journal of Medicine
Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Outcomes from TECOS
Jan Hein Cornel
Diabetes Obes Metab
Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
Marco Alings
Am Heart J
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Arend Mosterd
N Engl J Med
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
Jan Hein Cornel
Lancet
Cohort profile of BIOMArCS: the BIOMarker study to identify the Acute risk of a Coronary Syndrome-a prospective multicentre biomarker study conducted in the Netherlands
Ton Oude Ophuis; Victor Umans; Pranobe Oemrawsingh; Jurgen Akkerhuis; Carl Schotborgh; Eelko Ronner; Timo Lenderink; Anho Liem; Hong Kie The; Alexander Wardeh; Walter Hermans
BMJ Open
Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
Jan Hein Cornel
Journal of the American Heart Association
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
N Engl J Med
Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial
Marco Alings
Int J Cardiol
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial
Ton Oude Ophuis
JAMA
Short- and Long-Term Effect of Immediate Vasodilator Therapy in Acutely Decompensated Heart Failure: Results of the TRUE-AHF Trial
AHA 2016
An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention PIONEER AF-PCI
AHA 2016
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction. The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)
Ton Oude Ophuis
Circulation
ASSERT-II: Sub-Clinical AF (SCAF) in Older Asymptomatic Patients
AHA 2016
Subclinical AF Common in ASSERT 2, Stroke Implications Unclear
Medscape
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
Jan Hein Cornel
Diabetes Care
Characterisation and cholesterol management in patients with cardiovascular events and/or type 2 diabetes in the Netherlands
Anho Liem
Curr Med Res Opin
Individualising Anticoagulant Therapy in Atrial Fibrillation Patients
Marco Alings
Arrhythm Electrophysiol Rev
CHA 2 DS 2 -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm.
Dirk Lok
Eur J Heart Fail
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.
Ton Oude Ophuis
JAMA Cardiol.
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary-Revision 1
Marco Alings
Eur Heart J
Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial
Dirk Lok
Stroke
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial.
Jan Hein Cornel
J Am Coll Cardiol
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
Jan Hein Cornel
JAMA Cardiol.
Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial
Ton Oude Ophuis
Eur Heart J Acute Cardiovasc Care
Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial
Ton Oude Ophuis
JAMA
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54
Ton Oude Ophuis
Eur Heart J
Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure - Subanalysis of the WARCEF Trial.
Dirk Lok
Circ J
Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE)
Erik Badings
Diabetes Care
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.
Arend Mosterd
J Am Coll Cardiol
Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial
Jan Hein Cornel
Am Heart J
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
New England Journal of Medicine
Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin.
Dirk Lok
Am J Cardio
Results of ARTS-HF: finerenone versus eplerenone in patients with worsening chronic heart failure and diabetes and/or chronic kidney disease
ESC 2015
Discussant: ARTS-HF - finerenone versus eplerenone in patients with worsening chronic heart failure and diabetes and/or chronic kidney disease
ESC 2015
Evaluation of LIXisenatide in Acute Coronary Syndrome (ELIXA)
ESC 2015
Discussant: the ELIXA trial results – What do they mean?
ESC 2015
Impact of Sitagliptin on Heart Failure and Related Outcomes
ESC 2015
Discussant review: impact of Sitagliptin on Heart Failure and Related Outcomes
ESC 2015
SIGNIFY: Discussant review
ESC 2014
Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
Jan Hein Cornel
Eur Heart J Acute Cardiovasc Care
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
New England Journal of Medicine
Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial.
Ad van Boven
Am Heart J
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Aaf Kuijper
N Engl J Med
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
Marco Alings
Eur Heart J
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Jan Hein Cornel
Am J Cardiol
Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: warfarin versus aspirin in reduced cardiac ejection fraction trial substudy.
Dirk Lok
Circ Heart Fail
Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial.
Marco Alings
J Thromb Haemost
Long-term use of ticagrelor in patients with prior myocardial infarction
Aaf Kuijper; Ton Oude Ophuis
N Engl J Med
Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial.
Jan Hein Cornel
Am Heart J
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
Arend Mosterd
Eur Heart J
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
Arend Mosterd
Eur Heart J
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Arend Mosterd
Circulation
Association of quality of life with anticoagulant control in patients with heart failure: the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial.
Dirk Lok
Int J Cardiol
Cognitive function in ambulatory patients with systolic heart failure: insights from the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.
Dirk Lok
PLoS One
Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.
Dirk Lok
Cerebrovasc Dis
The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial.
Ton Oude Ophuis; Maarten van Hessen
Eur Heart J Acute Cardiovasc Care
Digoxin in patients with permanent atrial fibrillation: data from the RACE II study
Marco Alings
Heart Rhythm
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial
Aaf Kuijper
JAMA
Discussant: PARADIGM Heart Failure
ESC 2014
Results of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
ESC 2014
Ivabradine in patients with stable coronary artery disease without clinical heart failure: The results of SIGNIFY
ESC 2014
Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial.
Jan Hein Cornel
Am Heart J
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Aaf Kuijper
Circulation
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
Jan Hein Cornel
Thromb Haemost
Darapladib for preventing ischemic events in stable coronary heart disease
Aaf Kuijper
N Engl J Med
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial
Marco Alings
Eur Heart J
Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study.
Marco Alings
Eur J Heart Fail
Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial.
Dirk Lok
Circ Heart Fail
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Marco Alings
Circulation
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial.
Marco Alings
Eur Heart J
Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial.
Dirk Lok
Cerebrovasc Dis
Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study
Marco Alings; Frank Willems; Robert Tieleman; Raymond Tukkie
Neth Heart J
Randomized cluster crossover trials for reliable, efficient, comparative effectiveness testing: design of the Prevention of Arrhythmia Device Infection Trial (PADIT).
Marco Alings
Can J Cardiol
Rate control in atrial fibrillation, insight into the RACE II study
Ype Tuininga; Marco Alings
Neth Heart J
EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary
Marco Alings
Eur Heart J
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study.
Marco Alings
Eur Heart J
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Jan Hein Cornel
JAMA
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Aaf Kuijper
N Engl J Med
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
Aaf Kuijper
N Engl J Med
Apixaban after acute coronary syndrome in patients with heart failure: insights from the APPRAISE-2 trial.
Jan Hein Cornel
Eur Heart J
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
Marco Alings
Lancet Neurol
Vorapaxar in the secondary prevention of atherothrombotic events
Aaf Kuijper
N Engl J Med
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF
Aaf Kuijper
Lancet Neurol
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial
Aaf Kuijper
Diabetologia
Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population.
Erik Badings; Dirk Lok
J Diabetes
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Aaf Kuijper
N Engl J Med
Apixaban versus Warfarin in Patients with Atrial Fibrillation
N Engl J Med
Upstream therapy in patients with early atrial fibrillation: The relevance of the Routine versus Aggressive upstream rhythm Control for prevention of Early atrial fibrillation in heart failure (RACE 3) study
Marco Alings
Neth Heart J
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure).
Peter Dunselman
J Am Coll Cardiol
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Aaf Kuijper
Lancet
Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA).
Peter Dunselman
Eur J Heart Fail
Lenient versus strict rate control in patients with atrial fibrillation
Hans Bosker; Marco Alings; Jan Hein Cornel; Raymond Tukkie; Aaf Kuijper; Ype Tuininga
N Engl J Med
Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study).
Peter Dunselman
Am J Cardiol
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial.
Peter Dunselman
Eur J Heart Fail
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
Peter Dunselman
Circulation
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
Arnoud van 't Hof; Marco Alings; Dirk Lok; Anho Liem; Hans Kragten; Patrick Bronzwaer; Jan Hein Cornel; Michel Freericks; Bas Hamer; Karim Hamraoui; Gerard Hoedemaker; Aaf Kuijper; Gerard Linssen; Hans Louwerenburg; Peter Nierop; Toon Oomen; Koos Plomp; Bert Pos; Martijn van Eck; Frank Willems
Am Heart J
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
Peter Dunselman; Jan Hein Cornel
J Am Coll Cardiol
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide.
Peter Dunselman; Jan Hein Cornel
Eur J Heart Fail
Rosuvastatin in older patients with systolic heart failure.
Peter Dunselman; Jan Hein Cornel
N Engl J Med
Distal embolic protection during percutaneous coronary intervention in patients with acute coronary syndromes: the RUBY study.
Harry Suryapranata
Acute Card Care
A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics.
Peter Dunselman
Eur J Heart Fail
Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation--results from the RAte Control versus Electrical cardioversion (RACE) study.
Herre Kingma; Hans Bosker
Eur Heart J
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial.
Hans Kragten
Lancet
Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study.
Herre Kingma; Hans Bosker
J Am Coll Cardiol
The statin wars.
Peter Dunselman
Lancet
Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators
Peter Dunselman
Int J Cardiol
Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN)
Marcel Daniëls
Angiology
Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN)
Marcel Daniëls
Br J Clin Pharmacol
Addition of felodipine to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adequate beta-blockade. Results of the Felodipine ER and Metoprolol CR in Angina (FEMINA) Study. Working Group on Cardiovascular Research, The Netherlands (WCN)
Peter Dunselman; Anho Liem; Hans Kragten; Gerard Verdel
Eur Heart J
Monotherapy with nifedipine GITS compared with atenolol in stable angina pectoris. The Working Group on Cardiovascular Research (WCN)
Peter Dunselman
Br J Clin Pract Suppl
Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands Working Group on Cardiovascular Research (WCN)
Peter Dunselman; Dirk Lok; Herre Kingma
Int J Cardiol